Ursodeoxycholic acid inhibits clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection

Journal of Clinical Gastroenterology

Volumn 50, Issue 8, 2016, Pages 624-630

  Weingarden, Alexa R ^a   Chen, Chi ^a   Zhang, Ningning ^a   Graiziger, Carolyn T ^b   Dosa, Peter I ^c   Steer, Clifford J ^a   Shaughnessy, Megan K ^a,d   Johnson, James R ^a,d   Sadowsky, Michael J ^a   Khoruts, Alexander ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

bile acids; Clostridium difficile; pouchitis

Indexed keywords

URSODEOXYCHOLIC ACID; BILE ACID;

ADULT; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; DISEASE ASSOCIATION; DISEASE CONTROL; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; GROWTH INHIBITION; HUMAN; ILEITIS; INFECTION; MIDDLE AGED; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; RECURRENT DISEASE; SPORE GERMINATION; VEGETATIVE GROWTH; CASE REPORT; CLOSTRIDIUM INFECTION; FECES; IN VITRO STUDY; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; PATHOLOGY; TREATMENT OUTCOME;

BILE ACIDS AND SALTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; HUMANS; IN VITRO TECHNIQUES; MIDDLE AGED; POUCHITIS; RECURRENCE; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84944754899     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000427     Document Type: Article

References (36)

1. Zilberberg MD, Shorr AF, Kollef MH. Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005. Emerg Infect Dis. 2008; 14: 1756-1758.
2. Miller BA, Chen LF, Sexton DJ, et al. Comparison of the burdens of hospital-onset, healthcare facility-Associated Clostridium difficile Infection and of healthcare-Associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011; 32: 387-390.
3. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012; 55(suppl 2): S88-S92.
4. Magill SS, Edwards JR, Bamberg W, et al. Multistate pointprevalence survey of health care-Associated infections. N Engl J Med. 2014; 370: 1198-1208.
5. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med. 2008; 359: 1932-1940.
6. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2012; 9: 88-96.
7. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl JMed. 2013; 368: 407-415.
8. Drekonja D, Reich J, Gezahegn S, et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med. 2015; 162: 630-638.
9. Fuentes S, van Nood E, Tims S, et al. Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME J. 2014; 8: 1621-1633.
10. Weingarden AR, Chen C, Bobr A, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol. 2014; 306: G310-G319.
11. Weingarden A, Gonzalez A, Vazquez-Baeza Y, et al. Dynamic changes in short- And long-Term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome. 2015; 3: 10.
12. Seril DN, Shen B. Clostridium difficile infection in patients with ileal pouches. Am J Gastroenterol. 2014; 109: 941-947.
13. Hamilton MJ, Weingarden AR, Sadowsky MJ, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012; 107: 761-767.
14. Borody TJ, Leis S, Pang G, et al. Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. In: Rutgeerts P, ed. Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium difficile Infection. Waltham, MA: UpToDate 2014.
15. Petrof EO, Khoruts A. From stool transplants to nextgeneration microbiota therapeutics. Gastroenterology. 2014; 146: 1573-1582.
16. Wilson KH. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol. 1983; 18: 1017-1019.
17. Arroyo LG, Rousseau J, Willey BM, et al. Use of a selective enrichment broth to recover Clostridium difficile from stool swabs stored under different conditions. J Clin Microbiol. 2005; 43: 5341-5343.
18. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol. 2008; 190: 2505-2512.
19. Sorg JA, Sonenshein AL. Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J Bacteriol. 2009; 191: 1115-1117.
20. Sorg JA, Sonenshein AL. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol. 2010; 192: 4983-4990.
21. Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008; 65: 2461-2483.
22. Bliss DZ, Johnson S, Clabots CR, et al. Comparison of cycloserine-cefoxitin-fructose agar (CCFA) and taurocholate-CCFA for recovery of Clostridium difficile during surveillance of hospitalized patients. Diagn Microbiol Infect Dis. 1997; 29: 1-4.
23. Caporaso JG, Lauber CL, Walters WA, et al. Ultra-highthroughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 2012; 6: 1621-1624.
24. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009; 75: 7537-7541.
25. Edgar RC, Haas BJ, Clemente JC, et al. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics. 2011; 27: 2194-2200.
26. Cole JR, Wang Q, Cardenas E, et al. The Ribosomal Database Project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res. 2009; 37: D141-D145.
27. Heeg D, Burns DA, Cartman ST, et al. Spores of Clostridium difficile clinical isolates display a diverse germination response to bile salts. PLoS One. 2012; 7: e32381.
28. Hamilton MJ, Weingarden AR, Unno T, et al. High-Throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes. 2013; 4: 125-135.
29. Reshef L, Kovacs A, Ofer A, et al. Pouch inflammation is associated with a decrease in specific bacterial taxa. Gastroenterology. 2015; 149: 718-727.
30. Francis MB, Allen CA, Shrestha R, et al. Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS Pathog. 2013; 9: e1003356.
31. Giel JL, Sorg JA, Sonenshein AL, et al. Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One. 2010; 5: e8740.
32. Theriot CM, Koenigsknecht MJ, Carlson PE Jr, et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014; 5: 3114.
33. Buffie CG, Bucci V, Stein RR, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2014; 517: 205-208.
34. Koenigsknecht MJ, Theriot CM, Bergin IL, et al. Dynamics and establishment of Clostridium difficile infection in the murine gastrointestinal tract. Infect Immun. 2014; 83: 934-941.
35. Patel LN, Schairer J, Shen B. Fecal transplantation therapy for Clostridium difficile-Associated pouchitis. Int J Colorectal Dis. 2014; 29: 263-264.
36. Hofmann AF. Biliary secretion and excretion in health and disease: current concepts. Ann Hepatol. 2007; 6: 15-27.